INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/018501

A. CLASSIFIC Int.Cl ⁷	ATION OF SUBJECT MATTER C07K16/28, C12N15/11, 1/15, 1 A61K39/395, A61P35/00, 35/02			
According to Inte	ernational Patent Classification (IPC) or to both national	l classification and IPC	•	
B. FIELDS SE.				
Minimum docum Int.Cl ⁷	nentation searched (classification system followed by cl C07K16/28, C12N15/11, 1/15, 1 A61K39/395, A61P35/00, 35/02	1/19, 1/21, 5/00, C12P21		
Documentation s	earched other than minimum documentation to the exte	nt that such documents are included in the	fields searched	
*	· · · · · · · · · · · · · · · · · · ·	· .		
CAPlus	ase consulted during the international search (name of a (STN), MEDLINE (STN), BIOSIS (STN cot/PIR/GeneSeq, Genbank/EMBL/E), WPIDS(STN), JICST FI		
C. DOCUMEN	ITS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where ap		Relevant to claim No.	
P,X	BRUENKE J. et al., "A recombi single-chain Fv antibody agai II and FcyRIII (CD16) trigger of lymphoma cells", British of Haematology, April 2004, Vol. pages 167 to 179	nst HLA class s effective lysis Journal of	1-7,17-28	
Y	SEKIMOTO E. et al., "A recomb I-Specific Single Fv Diabody Death in Human Lymphoid Malic Blood, November, 2003, Vol.10 page 933a, Abstract. #3474	Induces Cell gnancies.",	1-14,16-28	
Further documents are listed in the continuation of Box C. See patent family annex.				
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "E" later document published after the international filing date of date and not in conflict with the application but cited to under the principle or theory underlying the invention can considered novel or cannot be considered to involve an invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can considered to involve an inventive step when the document of particular relevance; the claimed invention can conside		tion but cited to understand evention laimed invention cannot be ered to involve an inventive laimed invention cannot be tep when the document is documents, such combination art		
11 Marc	l completion of the international search ch, 2005 (11.03.05)	Date of mailing of the international sear 29 March, 2005 (29		
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer	-	
Facsimile No. Form PCT/ISA/21	0 (second sheet) (January 2004)	Telephone No.	•	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/018501

(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passage	es Relevant to claim No
Y	KIPRIYANOV SM. et al., "Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies", J.Mol.Biol., 2003, June, Vol.330, No.1, pages 99 to 111	1-14,16-28
Y	Laurent Genestier, et al., "Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I 1 Domain", Blood, 1997, Vol.90, No.9, pages 3629 to 3639	1-7,17-28
Y	Hudson PJ. et al., "High avidity scFv multimers: diabodies and triabodies.", J.Immunol.Methods., 1999, Vol.231, No. 1-2, p.177-89., Review	1-7,17-28
. Y	JP 7-503622 A (The Dow Chemical Co.), 20 April, 1995 (20.04.95), Full description & WO 94/13806 A1 & EP 628078 A & US 5877291 A1	1-7,17-28
Y	CO MS., et al., "A humanized antibody specific for the platelet integrin gpIIb/IIIa." J.Immunol., 1994, Vol.152, No.6, p.2968-76.	1-14,16-28
P,A	WO 2004/033499 Al (Chugai Pharmaceutical Co., Ltd.), 22 April, 2004 (22.04.04), (Family: none)	1-28
		,
		·